Rb蛋白保留型小细胞肺癌:具有治疗脆弱性的新实体?
小细胞肺癌(SCLC)侵袭性强且易耐药,转录谱分析已将其重新定义为具有不同治疗脆弱性的异质性亚型。本文聚焦保留功能性Rb蛋白的罕见SCLC亚群,转录组关联提示其与YAP1及非神经内分泌表达程序相关,临床前研究提示Rb保留可能对CDK4/6抑制等治疗具有独特敏感性。
要点
- Rb蛋白保留型SCLC可能是具有独特分子特征的新实体。
- 转录组关联提示Rb保留型SCLC与YAP1及非神经内分泌程序相关。
- 临床前研究提示Rb保留可能对CDK4/6抑制具有独特敏感性。
核心结论
- Rb蛋白保留型SCLC可能构成具有独特治疗脆弱性的新实体,分子分层有望改善SCLC治疗困境。
研究设计与样本
- 本文为基于近期转录谱分析与临床前研究的综述性论述,未报告具体样本量。
主要发现
- 转录组关联提示Rb保留型SCLC可能与YAP1及非神经内分泌表达程序相关。
- 临床前研究提示Rb蛋白保留可能对CDK4/6抑制具有独特治疗敏感性。
- CDK4/6抑制在临床前研究中不仅抑制肿瘤增殖,还可能重塑免疫微环境以增强免疫治疗反应。
- RB1功能状态可能调节对其他治疗方式的敏感性。
临床怎么用
- 整合RB1功能状态及其转录景观的分子分层策略,可能为SCLC精准治疗提供路线图。
局限性
- 将Rb蛋白保留型SCLC认定为独立实体仍在演进中,相关认识尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SCLC, frequently characterized by early metastasis and rapid development of therapy resistance, remains the most aggressive form of lung cancer. Recent transcriptional profiling has redefined SCLC as a heterogeneous spectrum of biologically distinct subtypes with potential differential therapeutic vulnerabilities, fostering optimism that molecular stratification may improve clinical outcomes. Within this framework, growing interest has focused on the rare subset of SCLC that retains functional retinoblastoma (Rb) protein. Although recognizing Rb-proficient SCLC as a distinct entity continues to evolve, transcriptomic correlations suggest possible links with YAP1 and non-neuroendocrine expression programs. Preclinical studies further indicate that Rb protein retention may confer unique therapeutic sensitivity, particularly to CDK4/6 inhibition, which not only suppresses tumor proliferation but also potentially reshapes the immune microenvironment to enhance immunotherapy responses. More importantly, RB1 functional status may also modulate sensitivity to additional therapeutic modalities, highlighting its broader relevance to the evolving SCLC treatment landscape. Integrating molecularly informed strategies accounting for RB1 proficiency and its transcriptional landscape will be pivotal to overcoming the long-standing therapeutic impasse in SCLC, offering a roadmap for the development of effective, precision-guided therapies.
引用
- Dowlati A, Ferdousi R, Ajay A, et al. Retinoblastoma-Proficient Small Cell Lung Cancer: A Novel Entity With Therapeutic Vulnerability? J Thorac Oncol. 2026. PMID: 41935666. doi:10.1016/j.jtho.2026.103714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。